Chemotherapy for advanced non-small cell lung cancer.
dc.contributor.author | Thatcher, Nick | |
dc.date.accessioned | 2009-10-13T08:23:01Z | |
dc.date.available | 2009-10-13T08:23:01Z | |
dc.date.issued | 2001-12 | |
dc.identifier.citation | Chemotherapy for advanced non-small cell lung cancer. 2001, 34 Suppl 2:S171-5 Lung Cancer | en |
dc.identifier.issn | 0169-5002 | |
dc.identifier.pmid | 11720761 | |
dc.identifier.uri | http://hdl.handle.net/10541/84115 | |
dc.description.abstract | Chemotherapy for advanced NSCLC in good performance status has survival benefit, reduces tumour symptoms and can improve quality of life. Future challenges include defining the optimal chemotherapy and incorporating the newer agents to improve patients' outcome. In particular treatment of the elderly and patients with poorer performance status need to be developed with more attention being paid to relief of symptoms and minimising treatment toxicity. | |
dc.language.iso | en | en |
dc.subject | Lung Cancer | en |
dc.subject | Cancer Staging | en |
dc.subject.mesh | Adult | |
dc.subject.mesh | Age Factors | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject.mesh | Carcinoma, Non-Small-Cell Lung | |
dc.subject.mesh | Health Status | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Lung Neoplasms | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Neoplasm Staging | |
dc.subject.mesh | Prognosis | |
dc.subject.mesh | Quality of Life | |
dc.subject.mesh | Randomized Controlled Trials as Topic | |
dc.subject.mesh | Survival Analysis | |
dc.title | Chemotherapy for advanced non-small cell lung cancer. | en |
dc.type | Article | en |
dc.contributor.department | Christie and Wythenshawe Hospitals, Wilmslow Road, M20 4BX, Manchester, UK. linda.aschcroft@christie-tr.nwest.nhs.uk | en |
dc.identifier.journal | Lung Cancer | en |
html.description.abstract | Chemotherapy for advanced NSCLC in good performance status has survival benefit, reduces tumour symptoms and can improve quality of life. Future challenges include defining the optimal chemotherapy and incorporating the newer agents to improve patients' outcome. In particular treatment of the elderly and patients with poorer performance status need to be developed with more attention being paid to relief of symptoms and minimising treatment toxicity. |